Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study

Leukemia and Lymphoma

Volumn 43, Issue 2, 2002, Pages 265-274

  Mantovani, Luisa ^a   Hasenclever, Dirk ^b   Krahl, Rainer ^b   Pönisch, Wolfram ^b   Herold, Michael ^c   Pasold, Rita ^d   Fiedler, Friedrich ^e   Dölken, Gottfried ^f   Kämpfe, Dietrich ^g   Schmoll, Hans Joachim ^h   Súbert, Rita ⁱ   Kubel, Martin ^b   Niederwieser, Dietger ^b   Helbig, Werner ^b  

^a Klinikum St Georg   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c HELIOS KLINIKUM ERFURT   (Germany)

^d KLINIKUM ERNST VON BERGMANN   (Germany)

^e Department of Internal Medicine III   (Germany)

^f UNIVERSITY OF GREIFSWALD   (Germany)

^g Hospital of Lüdenscheid   (Germany)

^h MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

ⁱ Klinikum Schwerin   (Germany)

Author keywords

Acute myeloid leukemia; Cytarabine; De novo; Moderate infusion rate

Indexed keywords

ANTHRACYCLINE; CYTARABINE; CYTARABINE TRIPHOSPHATE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; EYE DISEASE; FEASIBILITY STUDY; FEMALE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LEUKAPHERESIS; LEUKEMIA REMISSION; MALE; NAUSEA; NEUROTOXICITY; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; ALGORITHMS; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, PARENTERAL; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0036193018     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190290006035     Document Type: Article

References (29)

1. "Treatment of the newly diagnosed adult with de novo acute myeloid leukemia"
2. "Chemotherapy for acute myelogenous leukemia in children and adults"
3. "Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia"
4. "Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study"
5. "A Phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study"
6. "A randomized study of high-dose cytarabine in induction in acute myeloid leukemia"
7. "Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: A review and update results of the Australian Leukemia Study Group"
8. "Intensive post-remission chemotherapy in adults with acute myeloid leukemia"
9. "A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study"
10. "High-dose cytosine arabinoside therapy for refractory leukemia"
11. "Pharmacokinetics and cellular determinants of response to 1-beta-arabinofuranosyl-cytosine (Ara-C)"
12. "Saturation of 1-beta-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-beta-arabinofuranosylcytosine therapy"
13. "Saturation of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for intermediate-dose ara-c"
14. "Differences in the intracellular pharmacokinetics of cytosine arabinoside (ara-C) between circulating leukemic blasts and normal mononuclear blood cells"
15. "Ara-C metabolism in fresh leukemic blasts/normal bone marrow/hematopoetic stem cells and its impact on the lipid composition of leukemic cells (HL60)"
16. "High-dose cytarabine and daunorubicin induction and post remission chemotherapy for the treatment of acute myelogenous leukemia in adults"
17. "High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: A pilot study"
18. "Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission"
19. "High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia"
20. "Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia"
21. "Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia"
22. "High-dose versus intermediate-dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: Results of an age adjusted randomized comparison"
23. "Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: Data from AMLCG"
24. "High-dose cytosine arabinoside: Response to therapy in acute leukaemia and non-Hodgkin's lymphoma"
25. "Continuous-infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia"
26. "Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside"
27. "Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogenic bone marrow transplantation"
28. "Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia"
29. "Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: A pharamacologically based regimen"